. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Cancer Discov. 2018 May 17;8(7):822–835. doi: 10.1158/2159-8290.CD-18-0099

Table 1.

Clinical cohorts included in the study.

Cohort	Foundation Medicine (FM)	Stand Up to Cancer (SU2C)			Checkmate-057 (CM-057)	MDACC (PD-L1≥1%)
N	Foundation Medicine (FM)	MDACC	MSKCC	DFCI/MGH	Checkmate-057 (CM-057)	MDACC (PD-L1≥1%)
	924 (346 KRAS^MUT)	174			44	66
	924 (346 KRAS^MUT)	62	56	56	44	66
Nivolumab	NA	146			24	16
Pembrolizumab	NA	19			NA	40
Atezolizumab	NA	0			NA	5
a-PD(L)-1/a-CTLA-4	NA	9			NA	3
Docetaxel	NA	NA			20	NA
Other	NA	NA			NA	2^*

One patient with STK11/LKB1 mutant tumor was treated with Nivolumab and NKTR-214 (CD122-based agonist) and one patient with STK11/LKB1 wild-type tumor was treated with pembrolizumab and OX40 agonist.